Jacob Sands, MD - Assessing the Impact of Therapeutic Advances in SCLC: Instilling New Hope and Moving in Leaps and Bounds Toward Better Outcomes

PeerView Clinical Pharmacology CME/CNE/CPE Video

Go online to PeerView.com/VDU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Small cell lung cancer (SCLC) is known as an aggressive, rapidly progressing, and challenging thoracic malignancy. After lacking progress for decades, recent advances have finally led to approvals of new therapies that can improve outcomes and quality of life of patients with SCLC. Chemoimmunotherapy has become the new standard of care in the first-line setting, a novel transcription inhibitor has expanded very limited options in the second-line setting, and many ongoing trials and innovative approaches are anticipated to further escalate progress in this challenging subtype of lung cancer. These developments have also provided new hope to patients with SCLC, which makes it important to ensure that all patients have access to these therapies and can have the opportunity to benefit from them, as well as being encouraged to consider clinical trial participation. This activity, based on a recent PeerView Live event held during the 2022 ASCO Annual Meeting, focuses on evidence and practical guidance to help clinicians make the most of the latest treatment advances in SCLC. Essential data and best-practice recommendations are framed with cases to illustrate how to integrate the new therapeutic options into clinical practice. Investigational therapies and key ongoing trials will also be highlighted to continue to push for progress in better understanding the biology and expanding the treatment options for SCLC. Upon completion of this activity, participants should be better able to: Describe available and emerging therapeutics in SCLC, including immunotherapy, transcription inhibitors, myeloprotective therapies, and other treatment strategies, as well as emerging prospects in biomarker testing and subtyping that may help guide patient selection for different therapies; Apply the latest evidence and guidelines to incorporate new and emerging therapies into individualized treatment plans for eligible patients with SCLC in clinical practice or through clinical trial enrollment; Implement best practices for diagnosing and managing treatment-related toxicity in patients with SCLC; and Integrate multidisciplinary strategies and shared decision-making to ensure early diagnosis, individualized treatment, optimal management, and equitable care of patients with SCLC.